Nicole Richie, Ph.D.

Nicole Richie headshotNicole Richie, Ph.D., Global Head of Health Equity Science and Strategy, Global Product Development Medical Affairs

Nicole Richie, Ph.D. is the acting Global Head of Health Equity Science and Strategy where she leads the vision and serves as the product development lead responsible for developing and operationalizing strategies to drive greater inclusion of representative patient populations in clinical research and enrich data supporting the optimal use of Roche medicines.

Nicole has over ten years of clinical development experience in clinical science and operational strategy. Most recently, she functioned as the Clinical Science Business Strategy Leader and Chief of Staff to the Global Head of Immunology, Infectious Diseases, and Ophthalmology responsible for driving business operations and strategy.

Nicole is the Co-Lead/Co-Creator of Genentech/Roche’s Advancing Inclusive Research Program focused on addressing disparities in clinical research to advance science, support patient access, and improve outcomes. She also serves on the Advisory Board for the Genentech program “The Resilience Effect,” which is committed to addressing effects of childhood traumas, such as violence and structural racism, on long-term health.

Her work focused on strategies associated with enhancing the inclusion of racial and ethnic minorities in clinical cancer research has been published in the Journal of Clinical Oncology. She has authored peer-reviewed publications in translational medicine and clinical research across therapeutic areas and in early and late phase clinical studies and holds a patent application on methods for treating cancer using B-RAF inhibitors and immune checkpoint inhibitors.

Additional information:

Nicole received her Ph.D. from the University of Cincinnati College of Medicine in Pathobiology and Molecular Medicine, focused on the Molecular Biology of Cancer, and her B.S. in Biology from Indiana University. Prior to Genentech, Nicole led cross-functional teams in Pfizer’s early and late phase clinical studies in both large and small molecules as well as stem cell therapies in regenerative medicine. Nicole joined Genentech in the oncology clinical science group where she contributed to clinical strategy, led label expansions, and was the clinical lead on health authority interactions for Genentech’s first triple combination study.